Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1039
IPSCIO Record ID: 26696
IPSCIO Record ID: 26063
IPSCIO Record ID: 202848
This amended and restated agreement is to modify certain terms of the Agreement, and to license to Licensor all rights to continue to develop, and commercialize Verteporfin in the United States.
The Canadian Licensor grants to the Swiss Licensee and its Affiliates an exclusive, even to Licensor, perpetual license under the Licensor Technology, to research, develop, use, import, offer for sale and sell the Visudyne Product in the Field in the Licensees Territory. This license shall include the right to grant sublicenses through multiple tiers of sublicensees. Additionally, effective as of the Transition Effective Date, and subject to the terms and conditions of this Agreement, Licensor grants to Licensee and its Affiliates a non-exclusive, perpetual license under the Licensors Technology, to make and have made the Visudyne Product anywhere in the world solely for the purpose of exercising its rights under this Agreement, subject to Licensorâ€™s right to be the sole supplier of the Visudyne Product.
Licensor grants to Licensee and its Affiliates a non-exclusive, perpetual license under the Licensors Patents to research, develop, use, import, offer for sale and sell the Visudyne Product in the Field in the Licensees Territory. Additionally, effective as of the Transition Effective Date, and subject to the terms and conditions of this Agreement, Licensor grants a non-exclusive, perpetual license under the Patents, to make and have made the Visudyne Product anywhere in the world solely for the purpose of exercising its rights under this Agreement, subject to QLTâ€™s right to be the sole supplier of the Visudyne Product. These licenses shall include the right to grant sublicenses through multiple tiers of sublicensees.
The Product means (prior to the Transition Effective Date) BPD; ZnPc; and/or any additional Photosensitizer.
Patents relate to, but are not limited to, Wavelength-Specific Cytotoxic Agent; Derivatives for Photodynamic Therapy; and Liposome Compositions.
Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Visudyne is a light-activated drug used in photodynamic therapy for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
IPSCIO Record ID: 344589
Susceptibility Genes for Age Related Maculopathy (ARM) on Chromosome 10q26;
Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration;
Methods for Diagnosing, Preventing or Treating Drusen Formation;
Diagnostics and Therapeutics for Aortic Aneurysm;
Diagnostics and Therapeutics for Ocular disorders;
Diagnostics and Therapeutics for Drusen Associated Ocular Disorders;
Diagnostics and therapeutics for macular degeneration-related disorders;
Factor H-Based Diagnostics;
Methods and Compositions for Treating Ocular Disorders;
Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration;
Association of SNPs with Complement Related Diseases;
Genetic Variants Increase the Risk of Age-Related Macular Degeneration;
Diagnosis and Therapeutic Target for Macular Degeneration;
Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration;
Method Evolved Â· for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd);
Method of Detecting Ocular Diseases and Pathologic Conditions and Treatment of Same; and,
Genes Associated with Macular Degeneration.
AMD is an insidious progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. The end stage of this condition, called neovascular or 'wet AMD', develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. It is caused by abnormal growth of fragile and leaky blood vessels (choroidal neovascularization or 'CNV') in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.
Field shall mean any and all diagnostic, which includes prognostic, uses for research, laboratory developed tests or in vitro diagnostic tests markets, for use with any and all types of technology platforms.
IPSCIO Record ID: 3459
IPSCIO Record ID: 3199
Pursuant to the Amendment, the Licensor consented to the commercialization of EYLEA in Japan pursuant to a Co-Promotion and Distribution Agreement, which was executed concurrently with the execution of the Amendment.
EYLEAÂ® (aflibercept) Injection is indicated for the treatment of patients with neovascular (Wet) Age-related Macular Degeneration (AMD).
IPSCIO Record ID: 369411
5,283,255 – Wavelength-specific cytotoxic agents
5,756,540 – Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
5,399,583 – Method of treating skin diseases
Product(s) means goods manufactured using the Technology or Improvements, including Visudyne.
Visudyne bverteporfin therapy for the treatment of age-related macular degeneration and other conditions developed and manufactured by practicing one or more of the Valid Patent Claims Las outlined in Agreement) which fall within the definition of the Technology.
UBC Improvements Any and all improvements, variations, updates, modifications, enhancements and alterations related to the Technology, including all improvements, variations, updates, modifications, enhancements and alterations relating to photodynamic compounds or therapies, which are conceived, invented, developed and/or acquired solely by UBC Personnel, or by UBC Personnel jointly with the Licensee at any time after the Commencement Date, whether patentable or not,
(i) if patentable, claim priority from any of the patents or patent applications which comprise the Technology and can not be used or practiced without a licence of Technology,
(ii) if not patentable, which relate directly to the Technology, or
(iii) inventions or developments by Dr. Dolphin relating to photodynamic therapy.
Photodynamic therapy or â€œPDTâ€ uses photosensitizers (light activated drugs) in the treatment of disease.
Field of use is for the treatment of age-related macular degeneration and other conditions.
IPSCIO Record ID: 2709
Zinc, an essential nutrient, is the second most abundant trace element in the human body and the most abundant trace element in the eye. It is necessary for the activity of more than 200 enzymes and for the DNA binding capacity of over 400 nuclear regulatory elements. There is evidence that zinc may function as an antioxidant by protecting sulfhydryl groups from oxidation, competing with copper and iron to reduce the formation of hydroxyl radicals which are a result of redox cycling and by the induction of the antioxidant protein metallothionein (MT) which can scavenge damaging hydroxyls.
IPSCIO Record ID: 26094
IPSCIO Record ID: 5406
IPSCIO Record ID: 3092
In March 2011, the Licensor amended its License Agreement with the Licensee. Under the amendment, the Licensor will conduct at its own expense a Phase IIb trial of PF-655 in diabetic macular edema, under a protocol mutually agreed by both Parties. Under the amendment, the Licensor will deliver the trial data to the Licensee upon completion. After its review of the data, the Licensee will either make a milestone payment to the Licensor in an amount which exceeds the anticipated cost of the trial and resume responsibility for continued development of PF-655 at the Licensee's expense, or will terminate its license and return to the Licensor the rights to the product. In further consideration of the Licensor's conducting the Phase IIb trial, the Licensee agreed to increase the overall development and product approval milestone payments associated with the first ophthalmic use of PF-655 and to increase the royalty rates under the agreement. The Licensor may terminate the Phase IIb clinical trial if an independent monitoring committee determines futility at interim review points set forth in the protocol.
IPSCIO Record ID: 249885
AMD means Age-related macular degeneration.